摘要:
Disclosed are 2,5,6,7-tetranor-4,8-inter-m-phemylene PGI.sub.2 derivatives such as 16-methyl-2,5,6,7-tetranor-4,8-inter-m-phenylene PGI.sub.2 and methyl ester thereof, 17-methyl-2,5,6,7-tetranor-4,8-inter-m-phenylene PGI.sub.2 and methyl ester thereof, 15-phenyl-2,5,6,7,16,17,18,19,20-nonanor-4,8-inter-m-phenylene PGI.sub.2, 16-methyl-17-phenyl-2,5,6,7,18,19,20-heptanor-4,8-inter-m-phenylene PGI.sub.2, 16,16-dimethyl-17-phenyl-2,5,6,7,18,19,20-heptanor-4,8-inter-m-phenylene PGI.sub.2, 16-methyl-16-phenoxy-2,5,6,7,17,18,19,20-octanor-4,8-inter-m-phenylene PGI.sub.2, 16-methyl-16-phenoxy-2,5,6,7,18,19,20-heptanor-4,8-inter-m-phenylene PGI.sub.2 and methyl ester thereof, and 3-decarboxy-3-hydroxymethyl-16-methyl-16-phenoxy-2,5,6,7,18,19,20-heptanor-4,8-inter-m-phenylene PGI.sub.2, which are useful as pharmaceuticals.These compounds are useful as an antiulcer drug, antihypertensive drug, antithrombus drug or the like.
摘要:
Disclosed herein are novel prostaglandin I.sub.2 (PGI.sub.2) derivatives exhibiting excellent physiological activities, said derivatives being represented by the general formula: ##STR1## wherein R.sub.1, R.sub.2 and R.sub.3 are as defined herein.